Additionally, in NF‐κB‐activated cancers, in particular breast cancer, inhibition of the NF‐κB pathway with its inhibitors could promote CTR1‐copper upregulation, thus elevating MEK‐ERK and PDK1‐AKT pathways to form acquired resistance to NF‐κB inhibitors. Here, MAP2K7 is linked to cancer.